XFOR
Income statement / Annual
Last year (2025), X4 Pharmaceuticals Inc's total revenue was $35.11 M,
an increase of 1,273.21% from the previous year.
In 2025, X4 Pharmaceuticals Inc's net income was -$79.20 M.
See X4 Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$35.11 M |
$2.56 M |
$0.00 |
$0.00 |
$0.00 |
$3.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$6.26 M
|
$797.00 K
|
$0.00
|
$0.00
|
$1.89 M
|
$1.23 M
|
$672.00 K
|
$103.00 K
|
$195.00 K
|
$300.00 K
|
| Gross Profit |
$28.86 M
|
$1.76 M
|
$0.00
|
$0.00
|
-$1.89 M
|
$1.77 M
|
-$672.00 K
|
-$103.00 K
|
-$195.00 K
|
-$300.00 K
|
| Gross Profit Ratio |
0.82
|
0.69
|
0
|
0
|
0
|
0.59
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$72.72 M
|
$81.64 M
|
$72.02 M
|
$61.06 M
|
$48.76 M
|
$40.70 M
|
$30.16 M
|
$20.35 M
|
$28.13 M
|
$17.83 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$43.52 M
|
$61.52 M
|
$35.51 M
|
$27.02 M
|
$24.70 M
|
$20.94 M
|
$15.97 M
|
$8.64 M
|
$7.81 M
|
$6.22 M
|
| Other Expenses |
$0.00
|
-$105.00 M
|
$0.00
|
-$509.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$116.24 M
|
$38.16 M
|
$107.52 M
|
$87.57 M
|
$73.46 M
|
$61.64 M
|
$46.13 M
|
$28.98 M
|
$35.94 M
|
$24.05 M
|
| Cost And Expenses |
$122.00 M
|
$38.96 M
|
$107.52 M
|
$87.57 M
|
$75.35 M
|
$62.87 M
|
$46.80 M
|
$29.09 M
|
$36.13 M
|
$24.35 M
|
| Interest Income |
$4.58 M
|
$5.77 M
|
$4.58 M
|
$219.00 K
|
$10.00 K
|
$273.00 K
|
$1.20 M
|
$236.00 K
|
$214.00 K
|
$0.00
|
| Interest Expense |
$8.88 M
|
$8.77 M
|
$5.78 M
|
$3.99 M
|
$3.64 M
|
$2.69 M
|
$2.15 M
|
$720.00 K
|
$2.08 M
|
$2.52 M
|
| Depreciation & Amortization |
$1.28 M
|
$796.00 K
|
$419.00 K
|
$513.00 K
|
$1.89 M
|
$1.23 M
|
$672.00 K
|
$103.00 K
|
$195.00 K
|
$300.00 K
|
| EBITDA |
-$85.61 M |
-$27.58 M |
-$94.89 M |
-$89.33 M |
-$73.46 M |
-$58.64 M |
-$46.13 M |
-$28.98 M |
-$35.94 M |
-$24.05 M |
| EBITDA Ratio |
-2.44
|
-10.78
|
0
|
0
|
0
|
-19.55
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-2.47
|
-14.24
|
0
|
0
|
0
|
-19.96
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$7.73 M
|
-$739.00 K
|
$6.43 M
|
-$6.27 M
|
-$13.33 M
|
-$2.11 M
|
-$6.00 M
|
-$4.20 M
|
$2.26 M
|
$1.37 M
|
| Income Before Tax |
-$79.16 M
|
-$37.14 M
|
-$101.09 M
|
-$93.84 M
|
-$88.68 M
|
-$61.98 M
|
-$52.81 M
|
-$33.28 M
|
-$33.88 M
|
-$22.98 M
|
| Income Before Tax Ratio |
-2.25
|
-14.52
|
0
|
0
|
0
|
-20.66
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$41.00 K
|
$310.00 K
|
$78.00 K
|
$28.00 K
|
$17.00 K
|
$148.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$79.20 M
|
-$37.45 M
|
-$101.17 M
|
-$93.87 M
|
-$88.70 M
|
-$62.13 M
|
-$52.81 M
|
-$33.28 M
|
-$33.88 M
|
-$22.98 M
|
| Net Income Ratio |
-2.26
|
-14.65
|
0
|
0
|
0
|
-20.71
|
0
|
0
|
0
|
0
|
| EPS |
-1.87 |
-5.59 |
-17.07 |
-45.6 |
-119.58 |
-92.84 |
-138.94 |
-14238 |
-17767 |
-1737.74 |
| EPS Diluted |
-1.87 |
-5.59 |
-17.07 |
-45.6 |
-119.58 |
-92.84 |
-138.94 |
-14238 |
-17767 |
-1737.74 |
| Weighted Average Shares Out |
$42.29 M
|
$6.70 M
|
$5.93 M
|
$2.12 M
|
$858.30 K
|
$669.23 K
|
$384.33 K
|
$2.55 K
|
$1.91 K
|
$13.24 K
|
| Weighted Average Shares Out Diluted |
$42.29 M
|
$6.70 M
|
$5.93 M
|
$2.12 M
|
$858.30 K
|
$669.23 K
|
$384.33 K
|
$2.55 K
|
$1.91 K
|
$13.24 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
